Whereas Zhang et al excluded patients with metabolic and vascular comorbidities [22], known to be associated with elevated systemic FABP4 levels [23, 24], we did not because cardiovascular comorbidities are highly prevalent in patients with COPD (74% in our cohort) and we did not want to bias our study population. Here, FABP4 is linked to chronic obstructive pulmonary disease.